Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Kempharm Inc (KMPH)

Kempharm Inc (KMPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,902
  • Shares Outstanding, K 50,685
  • Annual Sales, $ 12,840 K
  • Annual Income, $ -24,520 K
  • 60-Month Beta 1.30
  • Price/Sales 0.90
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.95
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/12/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate 0.01
  • Number of Estimates 1
  • High Estimate 0.01
  • Low Estimate 0.01
  • Prior Year -0.46
  • Growth Rate Est. (year over year) +102.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1800 +25.00%
on 03/19/20
0.4700 -52.13%
on 03/03/20
-0.0780 (-25.74%)
since 02/28/20
3-Month
0.1800 +25.00%
on 03/19/20
0.7900 -71.52%
on 01/10/20
-0.1927 (-46.13%)
since 12/27/19
52-Week
0.1800 +25.00%
on 03/19/20
2.0000 -88.75%
on 06/20/19
-1.4450 (-86.53%)
since 03/29/19

Most Recent Stories

More News
KemPharm Submits KP415 NDA to the FDA for the Treatment of ADHD

If approved, KemPharm believes that KP415 may address several unmet needs, including earlier onset of action and longer duration of therapeutic effect vs. other available methylphenidate products

KMPH : 0.2250 (+4.60%)
KemPharma (KMPH) Reports Q4 Loss, Misses Revenue Estimates

KemPharma (KMPH) delivered earnings and revenue surprises of -28.57% and -62.81%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

KMPH : 0.2250 (+4.60%)
KemPharm Reports Fourth Quarter and Full-Year 2019 Financial Results

KP415 NDA Remains on Track for Q1 2020 Submission

KMPH : 0.2250 (+4.60%)
Nasdaq Grants KemPharm's Request for Extension to Comply with the Market Value of Listed Securities Continued Listing Requirement

KemPharm's Common Stock Listing Transfers to The Nasdaq Capital Market Effective Today

KMPH : 0.2250 (+4.60%)
KemPharm Announces Debt Restructuring with Deerfield and Delaware Street Capital

Principal and Interest Payments on Outstanding Debt in Principal Amount of $77.7M Pushed to March 31, 2021; Expected to Extend Cash Runway to New Maturity Date

KMPH : 0.2250 (+4.60%)
KemPharm Reports Third Quarter 2019 Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, November 14, 2019, at 5:30 p.m. ET

KMPH : 0.2250 (+4.60%)
KemPharm to Report Third Quarter 2019 Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for

KMPH : 0.2250 (+4.60%)
KemPharm Reports APADAZ(R) Will be Available Nationally Beginning in November 2019

KVK-Tech is Initially Stocking Selected Regions Based on Formulary Access

KMPH : 0.2250 (+4.60%)
KemPharm Presents Study Highlighting Patient-Friendly Dosing Properties of KP415 at the 66th Annual American Academy of Child & Adolescent Psychiatry Meeting

Data Demonstrate that KP415 Can Be Administered without Regard to Food; Can Be Mixed into Foods or Drink

PTCI : 0.5500 (+37.50%)
KMPH : 0.2250 (+4.60%)
ArQule (ARQL) in Focus: Stock Moves 6.2% Higher

ArQule (ARQL) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

KMPH : 0.2250 (+4.60%)
ARQL : 20.00 (+0.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade KMPH with:

Business Summary

KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303...

See More

Key Turning Points

2nd Resistance Point 0.2657
1st Resistance Point 0.2453
Last Price 0.2250
1st Support Level 0.2073
2nd Support Level 0.1897

See More

52-Week High 2.0000
Fibonacci 61.8% 1.3048
Fibonacci 50% 1.0900
Fibonacci 38.2% 0.8752
Last Price 0.2250
52-Week Low 0.1800

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar